CFZ533H
Total Payments
$10,410
Transactions
13
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $7,610 | 7 | 1 |
| 2019 | $2,800 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10,410 | 13 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED AND MULTI CENTER PLATFORM STUDY TO ASSESS EFFICACY AND SAFETY OF DIFFERENT INVESTIGATIONAL DRUGS IN PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA | Novartis Pharmaceuticals Corporation | $10,410 | 1 |
Top Doctors Receiving Payments for CFZ533H
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $7,210 | 12 |
| , M.D | Diagnostic Radiology | Manhasset, NY | $3,200 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $10,410
- Total Doctors 1
- Transactions 13
About CFZ533H
CFZ533H is a drug associated with $10,410 in payments to 1 healthcare providers, recorded across 13 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2019 to 2020. In 2020, $7,610 was paid across 7 transactions to 1 doctors.
The most common payment nature for CFZ533H is "Unspecified" ($10,410, 100.0% of total).
CFZ533H is associated with 1 research study, including "A RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED AND MULTI CENTER PLATFORM STUDY TO ASSESS EFFICACY AND SAFETY OF DIFFERENT INVESTIGATIONAL DRUGS IN PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA" ($10,410).